MONTREAL--(BUSINESS WIRE)--AngioChem, a biotechnology company discovering and developing drugs that are uniquely capable of crossing the blood-brain barrier, today announced that it will present updated data from clinical studies of ANG1005 at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2009 in Colorado. The data to be presented relate to the potential safety, efficacy and utility of ANG1005 in primary and secondary brain cancers.
